Novel vaccine technologies for the 21st century

doi:10.1038/s41577-019-0243-3

Review

. 2020 Feb;20(2):87-88.

doi: 10.1038/s41577-019-0243-3.

Novel vaccine technologies for the 21st century

John R Mascola¹, Anthony S Fauci²

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. afauci@niaid.nih.gov.

PMID: 31712767
PMCID: PMC7222935
DOI: 10.1038/s41577-019-0243-3

Review

Novel vaccine technologies for the 21st century

John R Mascola et al. Nat Rev Immunol. 2020 Feb.

. 2020 Feb;20(2):87-88.

doi: 10.1038/s41577-019-0243-3.

Authors

John R Mascola¹, Anthony S Fauci²

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. afauci@niaid.nih.gov.

PMID: 31712767
PMCID: PMC7222935
DOI: 10.1038/s41577-019-0243-3

Abstract

Novel approaches to vaccine development include structure-based immunogen design, gene-based vaccine platforms and formulation of recombinant antigens with potent adjuvants. These technologies are producing encouraging results in the development of vaccines for globally important diseases such as tuberculosis, influenza and respiratory syncytial virus. Here we highlight the most important developments in these areas over the past 18 months.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Cited by

A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade.
Zhang X, Tian H, Chen Y, Liang B, Nice EC, Huang C, Xie N, Zheng S. Zhang X, et al. J Nanobiotechnology. 2024 Sep 30;22(1):592. doi: 10.1186/s12951-024-02836-3. J Nanobiotechnology. 2024. PMID: 39343911 Free PMC article.
Ending the TB pandemic: the urgency of a new and improved TB vaccine and the World Health Organization's TB Vaccine Accelerator Council.
Adepoju VA, Onyezue OI. Adepoju VA, et al. Breathe (Sheff). 2023 Sep;19(3):230036. doi: 10.1183/20734735.0036-2023. Epub 2023 Sep 12. Breathe (Sheff). 2023. PMID: 37719240 Free PMC article.
The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants.
Yadegari I, Omidi M, Smith SR. Yadegari I, et al. Sci Rep. 2021 Nov 26;11(1):22970. doi: 10.1038/s41598-021-00083-2. Sci Rep. 2021. PMID: 34836984 Free PMC article.
Integrating Digital Health Solutions with Immunization Strategies: Improving Immunization Coverage and Monitoring in the Post-COVID-19 Era.
Pavia G, Branda F, Ciccozzi A, Romano C, Locci C, Azzena I, Pascale N, Marascio N, Quirino A, Matera G, Giovanetti M, Casu M, Sanna D, Ceccarelli G, Ciccozzi M, Scarpa F. Pavia G, et al. Vaccines (Basel). 2024 Jul 28;12(8):847. doi: 10.3390/vaccines12080847. Vaccines (Basel). 2024. PMID: 39203973 Free PMC article. Review.
Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine.
McAndrew T, Cambeiro J, Besiroglu T. McAndrew T, et al. Vaccine. 2022 Apr 1;40(15):2331-2341. doi: 10.1016/j.vaccine.2022.02.054. Epub 2022 Feb 28. Vaccine. 2022. PMID: 35292162 Free PMC article.

See all "Cited by" articles

References

1. Nabel GJ. Designing tomorrow’s vaccines. N. Engl. J. Med. 2013;368:551–560. doi: 10.1056/NEJMra1204186. - DOI - PMC - PubMed
1. Crank MC, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365:505–509. doi: 10.1126/science.aav9033. - DOI - PubMed
1. Marcandalli J, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019;176:1420–1431. doi: 10.1016/j.cell.2019.01.046. - DOI - PMC - PubMed
1. Paules CI, et al. Chasing seasonal influenza - the need for a universal influenza vaccine. N. Engl. J. Med. 2018;378:7–9. doi: 10.1056/NEJMp1714916. - DOI - PubMed
1. Pardi N, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 2018;9:3361. doi: 10.1038/s41467-018-05482-0. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Nabel GJ. Designing tomorrow’s vaccines. N. Engl. J. Med. 2013;368:551–560. doi: 10.1056/NEJMra1204186. - DOI - PMC - PubMed

[2] Nabel GJ. Designing tomorrow’s vaccines. N. Engl. J. Med. 2013;368:551–560. doi: 10.1056/NEJMra1204186. - DOI - PMC - PubMed

[3] Crank MC, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365:505–509. doi: 10.1126/science.aav9033. - DOI - PubMed

[4] Crank MC, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365:505–509. doi: 10.1126/science.aav9033. - DOI - PubMed

[5] Marcandalli J, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019;176:1420–1431. doi: 10.1016/j.cell.2019.01.046. - DOI - PMC - PubMed

[6] Marcandalli J, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019;176:1420–1431. doi: 10.1016/j.cell.2019.01.046. - DOI - PMC - PubMed

[7] Paules CI, et al. Chasing seasonal influenza - the need for a universal influenza vaccine. N. Engl. J. Med. 2018;378:7–9. doi: 10.1056/NEJMp1714916. - DOI - PubMed

[8] Paules CI, et al. Chasing seasonal influenza - the need for a universal influenza vaccine. N. Engl. J. Med. 2018;378:7–9. doi: 10.1056/NEJMp1714916. - DOI - PubMed

[9] Pardi N, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 2018;9:3361. doi: 10.1038/s41467-018-05482-0. - DOI - PMC - PubMed

[10] Pardi N, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 2018;9:3361. doi: 10.1038/s41467-018-05482-0. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Novel vaccine technologies for the 21st century

Affiliations

Novel vaccine technologies for the 21st century

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous